Recent Analysts’ Ratings Updates for Tarsus Pharmaceuticals (TARS)

Several brokerages have updated their recommendations and price targets on shares of Tarsus Pharmaceuticals (NASDAQ: TARS) in the last few weeks:

• 7/21/2026 – Tarsus Pharmaceuticals had its price target lowered by Guggenheim from $90.00 to $89.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Tarsus Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/12/2026 – Tarsus Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/9/2026 – Tarsus Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $88.00 price target on the stock.
• 6/28/2026 – Tarsus Pharmaceuticals was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/20/2026 – Tarsus Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/6/2026 – Tarsus Pharmaceuticals was upgraded by Wall Street Zen from “hold” to “buy”.

Insider Buying and Selling

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 10,000 shares of the business’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $61.55, for a total transaction of $615,500.00. Following the transaction, the chief executive officer owned 847,991 shares in the company, valued at $52,193,846.05. The trade was a 1.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director William J. Phd Link sold 12,500 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $62.12, for a total value of $776,500.00. Following the completion of the sale, the director owned 106,786 shares of the company’s stock, valued at approximately $6,633,546.32. This trade represents a 10.48% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 39,850 shares of company stock valued at $2,452,821. 9.64% of the stock is owned by company insiders.

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.